Reckweg Johannes T, Mason Natasha L, Theunissen Eef L, Svendsen Claus B, Terwey Theis H, Ramaekers Johannes G
Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, Netherlands.
GH Research, Dublin, Ireland.
Front Psychol. 2025 Jun 2;16:1543640. doi: 10.3389/fpsyg.2025.1543640. eCollection 2025.
A three-item Peak Experience Scale (PES) was developed to rapidly evaluate the strength of the psychoactive experience, and to guide the dosing regimen, of the psychedelic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT; mebufotenin). This paper aims to compare the PES with a range of established questionnaires designed to evaluate the psychedelic experience. Data were gathered from three separate studies in which a 5-MeO-DMT formulation (GH001) was administered via pulmonary inhalation to healthy volunteers and patients with treatment resistant depression ( = 84) as either single doses (0 [placebo], 2, 6, 12, 18 mg) or an incremental individualized dosing regimen (IDR). Apart from the PES, participants also completed the Mystical Experience Questionnaire (MEQ-30), the Challenging Experience Questionnaire (CEQ), the Ego Dissolution Inventory (EDI) and the 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC). The 5-MeO-DMT formulation produced a significant, dose-related increase in PES ratings, with maximal ratings being achieved after the IDR. A principal component analysis (PCA) of the PES items identified a single primary component explaining 83.5% of the variance. PES items also displayed a strong internal consistency (Cronbach's = 0.896). A PCA across all questionnaires indicated a strong and unidimensional loading of the PES, MEQ, EDI and the 5D-ASC, suggesting high interrelatedness. Likewise, individual ratings on the PES were highly correlated to those on the PES, MEQ, EDI and the 5D-ASC, but not the CEQ. The PES is concluded to be an effective tool to rapidly assess the strength of the psychedelic experience with 5-MeO-DMT. The PES could prove useful to gain fast insight into the strength of a psychedelic dose in individual patients and potentially guide dose and re-dose selection of rapid-acting psychedelics.
开发了一个包含三个条目的高峰体验量表（PES），用于快速评估精神活性体验的强度，并指导致幻剂5-甲氧基-N,N-二甲基色胺（5-MeO-DMT；美布托宁）的给药方案。本文旨在将PES与一系列旨在评估致幻体验的既定问卷进行比较。数据来自三项独立研究，其中5-MeO-DMT制剂（GH001）通过肺部吸入给予健康志愿者和难治性抑郁症患者（n = 84），给药方式为单次剂量（0[安慰剂]、2、6、12、18毫克）或递增个体化给药方案（IDR）。除了PES，参与者还完成了神秘体验问卷（MEQ-30）、挑战性体验问卷（CEQ）、自我解体量表（EDI）和五维意识状态改变评定量表（5D-ASC）。5-MeO-DMT制剂使PES评分显著增加且与剂量相关，在IDR后达到最高评分。对PES条目进行主成分分析（PCA）确定了一个单一主要成分，解释了83.5%的方差。PES条目还显示出很强的内部一致性（克朗巴哈系数 = 0.896）。对所有问卷进行的PCA表明，PES、MEQ、EDI和5D-ASC具有很强的单维负荷，表明它们之间具有高度相关性。同样，PES上的个体评分与PES、MEQ、EDI和5D-ASC上的评分高度相关，但与CEQ无关。结论是，PES是一种有效工具，可快速评估5-MeO-DMT致幻体验的强度。PES可能有助于快速了解个体患者中致幻剂量的强度，并可能指导速效致幻剂的剂量和重复给药选择。
